Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to $369000.0.

  • KalVista Pharmaceuticals' Gains from Investment Securities rose 8923.08% to $369000.0 in Q2 2025 from the same period last year, while for Apr 2025 it was $1.5 million, marking a year-over-year increase of 1547.17%. This contributed to the annual value of $1.6 million for FY2025, which is 1781.13% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $369000.0 for Q2 2025, which was up 8923.08% from $649000.0 recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Gains from Investment Securities peaked at $649000.0 during Q4 2024, and registered a low of $195000.0 during Q2 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $317000.0 (2024), whereas its average is $380000.0.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Gains from Investment Securities soared by 95.54% in 2024 and then surged by 8923.08% in 2025.
  • Over the past 3 years, KalVista Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $595000.0 in 2023, then rose by 9.08% to $649000.0 in 2024, then plummeted by 43.14% to $369000.0 in 2025.
  • Its Gains from Investment Securities stands at $369000.0 for Q2 2025, versus $649000.0 for Q4 2024 and $317000.0 for Q3 2024.